What Does This Rejection Mean for Eli Lilly?

The FDA's rejection of Lilly's SGLT-2 inhibitor over manufacturing issues at a partner is another self-inflicted operational challenge.

Mar 6, 2014 at 2:00PM

In the extremely competitive world of Big Pharma, companies have to be careful to keep all of their ducks in neat little rows. I have made no secret of the fact that I believe Lilly (NYSE:LLY) struggles in that regard, and yesterday's surprising announcement that the FDA rejected empagliflozin over manufacturing issues at a plant owned and operated by its partner Boehringer Ingelheim doesn't help matters.

Details matter
The FDA most often rejects new drug applications due to concerns that efficacy has not been adequately substantiated, the drug in question is not safe, or there is not a sufficient trade-off between risk and benefit. A lesser known, but still important, part of the process is that the facility in which the new drug is to be made must be in compliance with FDA rules.

It is that latter point that has tripped up Lilly. Lilly announced on Wednesday morning that the FDA had rejected its application for a new SGLT-2 inhibitor called empagliflozin due to cited deficiencies at the Boehringer Ingelheim plant where the drug is to be manufactured. BI and Lilly became partners in diabetes drug development back in 2011, with BI combining its R&D and manufacturing abilities with Lilly's marketing muscle in the diabetes space.

A BI representative later indicated that the company has responded to the previously identified issues at the plant and that an FDA reinspection was under way. Assuming that the FDA is satisfied with the response, that rejection should be reversed but it will likely take at least six months for the full inspection process to end and for the agency to reconsider the submission.

Time to market matters
With Lilly/BI's challenges, Johnson & Johnson (NYSE:JNJ) and AstraZeneca (NYSE:AZN) stand to benefit at least a little bit. Johnson & Johnson is nearing the one-year anniversary for the approval of its SGLT-2 drug Invokana and the drug leads the nascent space for SGLT-2 inhibitors. AstraZeneca, which got approval for Farxiga about two months ago (January 8, 2014) has actually since its new drug tracking ahead of Invokana in these very early days of the launch.

Branded drugs may have useful commercial lives of 10 to 15 years, if not longer, so does a six-month delay really matter? In the case of diabetes medications the answer may well be yes. Diabetes is not like depression, where patients will often cycle through multiple drugs before settling on one that works, and doctors and patients tend to stick with what works.

By being the third to arrive at the table, Lilly has a bigger challenge ahead in convincing doctors to switch their patients to its SGLT-2 drug. One factor that should play in Lilly's favor, though, is the ability to sell combo-drugs – combinations of empagliflozin and metformin and empagliflozin and BI's DPP-IV inhibitor Tradjenta – that Johnson & Johnson cannot match.

Ultimately the rejection of empagliflozin is likely to be a temporary glitch – BI will almost certainly get the manufacturing issues resolved, the FDA will reverse its decision and approve the drug, and everyone will go on their merry way. But it may well prove to be a headwind that has some permanent repercussions on the drug's peak sales.

Not all bad news
The rejection of empagliflozin may have come as a negative surprise, but the company has had some recent positive news on the diabetes front. The company's AWARD-6 non-inferiority study comparing Lilly/BI's dulaglutide (a long-acting GLP-1 agonist) to Novo Nordisk's (NYSE:NVO) once-daily Victoza did achieve its goal of non-inferiority in HbA1c reduction at 26 weeks, with no untoward or new safety issues.

Non-inferiority may sound like weak tea, but it's actually a pretty significant achievement. AstraZeneca's once-weekly GLP-1 agonist Bydureeon was not able to show equivalent efficacy to Victoza and, combined with some administration issues with Bydureon, Novo Nordisk has been able to maintain leading (approximately two-thirds) market share, despite the fact that Victoza users must inject it every day.

With dulaglutide showing better efficacy and offering once-weekly administration (not to mention the possibility of drug and insulin combos with other Lilly products), Lilly has a chance to gain some business here before Novo Nordisk gets its own long-acting version on the market (likely not until 2017, given pivotal data on long-acting semaglutide is expected in early 2016).

The Bottom Line
I don't want to beat up on Lilly all that much over this rejection. First, this is something that can and does happen to many drug companies. Second, it wasn't a Lilly facility that was the issue. Even so, it is another bump in the road for a company that has already given its shareholders a rough ride. Although the AWARD-6 data is far more positive for Lilly than the empagliflozin news is negative, I still am not all that favorably disposed toward Lilly at this time.

6 potentially better growth opportunities
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers